Anne Kasper

机构：Alnylam Pharmaceuticals (United States)

发表论文 18 篇 · 总被引 387 次 · h-index 5

代表论文

• Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates (2022 · Nature Biotechnology · 被引 254)
• Gene activation of SMN by selective disruption of lncRNA-mediated recruitment of PRC2 for the treatment of spinal muscular atrophy (2017 · Proceedings of the National Academy of Sciences · 被引 83)
• Counteracting Angiotensinogen Small-Interfering RNA-Mediated Antihypertensive Effects With REVERSIR (2024 · Hypertension · 被引 21)
• Blood pressure‐independent renoprotective effects of small interference RNA targeting liver angiotensinogen in experimental diabetes (2022 · British Journal of Pharmacology · 被引 12)
• High resistance barrier and prophylactic protection in preclinical models of SARS-CoV-2 with two siRNA combination (2024 · Nucleic Acids Research · 被引 9)
• Kidney Arteriolar Responses to Liver‐Targeted Small Interference RNA Targeting Angiotensinogen in Diabetic Rats: Comparison With Other Renin‐Angiotensin System Blockers (2025 · Journal of the American Heart Association · 被引 4)